University of North Carolina at Chapel Hill School of MedicineChapel Hill, NC
71 - Efficacy of Mirikizumab by Baseline Disease Location in Moderately to Severely Active Crohn’s Disease: Results of the Phase 3 VIVID-1 Study
Wednesday, October 30, 20249:30 AM – 9:40 AM ET